Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Amplia.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: More biotechs change their names, but will they smell just as sweet?
Health & Biotech
Bargain Barrel: Four ASX cancer-fighting stocks with market caps under $35 million
Health & Biotech
The storied Australian drug developer turning his skills to funds management
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Health Check: Rats – and investors – are happy as Nyrada forges ahead with its first human trial
Health & Biotech
Amplia CEO co-recipient of 2024 Prime Minister’s Prize for Innovation
News
Closing Bell: Most ASX sectors flash green on another record day; Mithril strikes gold in Mexico
News
Market Highlights: Nasdaq soars and S&P 500 hits record; Ellison climbs rich ladder on Oracle’s AI plans
Health & Biotech
MoneyTalks: Pengana’s James McDonald reveals his top three ASX biotechs
Health & Biotech
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
Health & Biotech
ASX Health Stocks: Amplia’s pancreatic cancer drug shows progress
Health & Biotech
ASX Health Stocks: LBT skyrockets 40pc after winning deal with global pharma, AstraZeneca
News
Closing Bell: ASX, Nikkei fight back; RBA refuses to budge on interest rates
Health & Biotech
ASX Health Stocks: Amplia sees new success in pancreatic cancer trial
News
Market Highlights: Not much spared on chopping block after another big selloff, Wall Street loses US$3.5 trillion
News
